Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.64 |
| ▸ | TUBB | P07437 | 1/20 | 0.64 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.64 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.64 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.64 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.64 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.64 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.64 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.64 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.64 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.64 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.64 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.64 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.64 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528482 | 0.90 | NR4A2 (0.67) | NR4A2MEN1KMT2ATUBB4ATUBB | |
| SCHEMBL3275504 | 0.90 | MEN1 (0.65) | NR4A2MEN1KMT2ATUBB4ATUBB | |
| SCHEMBL3246965 | 0.89 | NR4A2 (0.60) | NR4A2MEN1KMT2ATUBB4ATUBB | |
| SCHEMBL30688567 | 0.88 | NR4A2 (0.60) | NR4A2MEN1KMT2ATUBB4ATUBB | |
| SCHEMBL31305695 | 0.86 | NR4A2 (0.57) | NR4A2MEN1KMT2ATUBB4ATUBB | |
| SCHEMBL31570758 | 0.83 | NR4A2 (1.00) | NR4A2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5508274 | 0.83 | ALDH1A1 (0.65) | NR4A2MEN1KMT2ATUBB4ATUBB | |
| SCHEMBL6216675 | 0.83 | NR4A2 (1.00) | NR4A2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29736213 | 0.83 | ALDH1A1 (0.65) | NR4A2MEN1KMT2ATUBB4ATUBB | |
| SCHEMBL30572914 | 0.83 | KDM4E (0.69) | NR4A2MEN1KMT2ATUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092020-A1 | IDO/TDO Inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12209079-B2 | IDO/TDO inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-01-28 | — | — | US | disclosed |
| US-20220380305-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. | 2022-12-01 | — | — | US | disclosed |
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| EP-2731436-B1 | 2-(PYRROLO[2,3-B]PYRIDINE-5-YL)-2-(T-BUTOXY)-ACETIC ACID DERIVATIVES AS HIV REPLICATION INHIBITORS FOR THE TREATMENT OF AIDS | VIIV HEALTHCARE UK LTD (GB) | 2017-03-08 | — | — | EP | disclosed |
| US-9012642-B2 | Pyrrolopyridinone compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| EP-2731436-A1 | AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV Healthcare UK Limited (GB) | 2014-05-21 | — | — | EP | disclosed |
| EP-1966134-B1 | NOVEL FUSED PYRROLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20090028796-A1 | PESTICIDAL COMPOSITION COMPRISING INDOLE DERIVATES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2009-01-29 | — | — | US | disclosed |
| EP-1966134-A1 | NOVEL FUSED PYRROLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| CN-101142185-A | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2008-03-12 | — | — | CN | disclosed |
| WO-2007068621-A1 | NOVEL FUSED PYRROLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142452-A1 | Fused pyrrole derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-21 | — | — | US | disclosed |
| EP-1042287-B1 | INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-6337344-B1 | ANTICOAGULANTS AND ENZYME INHIBITORS FOR CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-08 | — | — | US | disclosed |
| EP-1042287-A1 | INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA | Aventis Pharma Deutschland GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033800-A1 | INDOLE DERIVATIVES AS INHIBITORS OR FACTOR XA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-08 | — | — | WO | disclosed |
| US-5786361-A | ANTIATHEROSCLEROSIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209079-B2 | IDO/TDO inhibitor | IDO1, IDO2, TDO2 | NR4A2 1196/4885MEN1 1174/4885KMT2A 800/4885 |
| US-20070142452-A1 | Fused pyrrole derivatives | CMA1, PREP, CPA3 | NR4A2 2444/4885MEN1 2461/4885KMT2A 3786/4885 |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | DHPS, PRNP, TYMP | NR4A2 2906/4885MEN1 4374/4885KMT2A 1620/4885 |
| US-20090028796-A1 | PESTICIDAL COMPOSITION COMPRISING INDOLE DERIVATES | IDO1, IDO2, INMT | NR4A2 4675/4885MEN1 3306/4885KMT2A 3257/4885 |
| US-20200239452-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | NR4A2 1196/4885MEN1 1174/4885KMT2A 800/4885 |
| US-20250092020-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | NR4A2 1196/4885MEN1 1174/4885KMT2A 800/4885 |
| US-20220380305-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | NR4A2 1365/4885MEN1 693/4885KMT2A 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.